Amanote Research

Amanote Research

    RegisterSign In

Intranasal Delivery of Recombinant AAV Containing BDNF Fused With HA2TAT: A Potential Promising Therapy Strategy for Major Depressive Disorder

Scientific Reports - United Kingdom
doi 10.1038/srep22404
Full Text
Open PDF
Abstract

Available in full text

Categories
Multidisciplinary
Date

March 3, 2016

Authors
Xian-cang MaPeng LiuXiao-ling ZhangWen-hui JiangMin JiaCai-xia WangYing-ying DongYong-hui DangCheng-ge Gao
Publisher

Springer Science and Business Media LLC


Related search

A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats With Post-Stroke Depression

Neuropsychiatric Disease and Treatment
2020English

A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder

Biological Psychiatry
Biological Psychiatry
2014English

Major Depressive Disorder

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2018English

Major Depressive Disorder

English

Major Depressive Disorder

2013English

Dental Patients With Major Depressive Disorder

Current Oral Health Reports
2014English

Fluoxetine Plus Cognitive Behavioural Therapy Was Most Effective for Adolescents With Major Depressive Disorder

Evidence-Based Medicine
Medicine
2005English

A Patient With Major Depressive Disorder Recovered With Repetitive Transcranial Magnetic Stimulation After Electroconvulsive Therapy

Kitakanto Medical Journal
Medicine
2017English

Venlafaxine Versus Sertraline for Major Depressive Disorder

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy